Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415506 · ClinicalTrials.gov registry record · Phase 1
Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
A Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00415506 is a Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 20 participants.
The verdict
NCT00415506, a Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of Rituximab in refractory scleritis and non-infectious orbital inflammation.
Interventions
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00415506
The ClinicalTrials.gov registry entry for NCT00415506 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT00415506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00415506 about?
NCT00415506 is a clinical study titled "Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation". The purpose of this study is to assess the safety and tolerability of Rituximab in refractory scleritis and non-infectious orbital inflammation.
What is the current status of trial NCT00415506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-01. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00415506?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00415506?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.